Document Detail


Do randomized controlled trials discuss healthcare costs?
MedLine Citation:
PMID:  20808794     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Healthcare costs, particularly pharmaceutical costs, are a dominant issue for most healthcare organizations, but it is unclear if randomized controlled trials (RCTs) routinely discuss costs. Our objective was to assess the frequency and factors associated with the inclusion of costs in RCTs.
METHODS AND FINDINGS: We randomly sampled 188 RCTs spanning three years (2003-2005) from six high impact journals. The sample size for RCTs was based on a calculation to estimate the inclusion of actual drug costs with a precision of +/-3%. Two reviewers independently extracted cost data and study characteristics. Frequencies were calculated and potential characteristics associated with the inclusion of costs were explored. Actual drug costs were included in 4.7% (9/188) of RCTs; any actual costs were included in 7.4% (14/188) of RCTs; and any mention of costs was included in 27.7% (52/188) of RCTs. As the amount of industry funding increased across RCTs, from non-profit to mixed to fully industry funded RCTs, there was a statistically significant reduction in the number of RCTs with any actual costs (Cochran-Armitage test, p = 0.005) and any mention of costs (Cochran-Armitage test, p = 0.02). Logistic regression analysis also indicated funding was associated with the inclusion of any actual cost (OR = 0.34, p = 0.009) or any mention of costs (OR = 0.63, p = 0.02). Journal, study conclusions, study location, primary author's country and product age were not associated with inclusion of cost information.
CONCLUSION: While physicians are encouraged to consider costs when prescribing drugs for their patients, actual drug costs were provided in only 5% of RCTs and were not mentioned at all in 72% of RCTs. Industry funded trials were less likely to include cost information. No other factors were associated with the inclusion of cost information.
Authors:
G Michael Allan; Christina Korownyk; Kate LaSalle; Ben Vandermeer; Victoria Ma; Douglas Klein; Donna Manca
Related Documents :
9792474 - Societal and personal costs of obesity.
15919624 - A synthesis of cost-utility analysis literature in infectious disease.
15151194 - Pharmaceutical "charge compression" under the medicare outpatient prospective payment s...
17980574 - Separate collection of the biodegradable fraction of msw: an economic assessment.
9792474 - Societal and personal costs of obesity.
17312684 - Early childhood experiences and current emotional distress: what do they tell us about ...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't     Date:  2010-08-23
Journal Detail:
Title:  PloS one     Volume:  5     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-11-04     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e12318     Citation Subset:  IM    
Affiliation:
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada. michael.allan@ualberta.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Health Care Costs*
Humans
Pharmaceutical Preparations / economics
Randomized Controlled Trials as Topic*
Sample Size
Chemical
Reg. No./Substance:
0/Pharmaceutical Preparations
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very prete...
Next Document:  Competing activities of heterotrimeric G proteins in Drosophila wing maturation.